Advertisement
Screener

DiaMedica Therapeutics Inc. (DMAC) Graph

DMAC Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue including tax (m); Research and development $8.15M; Operating expenses (m); Income tax $7.00K.
  • 2026-03-31: Revenue including tax (m); Research and development $7.99M; Operating expenses (m); Income tax $7.00K.
  • 2025-12-31: Revenue including tax (m); Research and development $6.70M*; Operating expenses (m); Income tax $10.00K*.
  • 2025-09-30: Revenue including tax (m); Research and development $6.44M; Operating expenses (m); Income tax $6.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$8.15M(m)$7.00K-$10.14M
2026-03-31(m)$7.99M(m)$7.00K-$10.04M
2025-12-31(m)$6.70M*(m)$10.00K*-$8.74M*
2025-09-30(m)$6.44M(m)$6.00K-$8.62M
2025-06-30(m)$5.82M(m)$6.00K-$7.70M
2025-03-31(m)$5.66M(m)$6.00K-$7.71M
2024-09-30(m)$4.98M(m)$7.00K-$6.27M
2024-06-30(m)$3.93M(m)$7.00K-$5.12M
2024-03-31(m)$3.68M(m)$7.00K-$5.15M
2023-09-30(m)$3.27M(m)$7.00K-$4.47M
2023-06-30(m)$2.54M(m)$7.00K-$4.48M
2023-03-31(m)$3.62M(m)$7.00K-$5.27M
2022-09-30(m)$1.64M(m)$7.00K-$3.06M
2022-06-30(m)$1.96M(m)$7.00K-$3.36M
2022-03-31(m)$1.97M(m)$7.00K-$3.51M
2021-09-30(m)$2.33M(m)$7.00K-$3.45M
2021-06-30(m)$2.16M(m)$7.00K-$3.27M
2021-03-31(m)$2.41M(m)$7.00K-$3.62M
2020-09-30(m)$2.16M(m)$2.00K-$3.19M
2020-06-30(m)$1.60M(m)$9.00K-$2.47M
2020-03-31(m)$1.35M(m)$9.00K-$2.42M
2019-09-30(m)$1.62M(m)$12.00K-$2.45M
2019-06-30(m)$1.87M(m)$8.00K-$2.47M
2019-03-31(m)$2.61M$3.42M$9.00K-$3.25M
2018-09-30$500.00K$1.21M(m)$57.00K-$1.39M
2018-06-30(m)$1.07M(m)$16.00K-$1.74M
2018-03-31(m)$791.00K$1.31M$1.00K-$650.00K

Revenue and expense 6 month

Period endResearch and developmentIncome taxNet income
2026-06-30$16.14M$14.00K-$20.18M
2025-06-30$11.48M$12.00K-$15.41M
2024-06-30$7.60M$14.00K-$10.27M
2023-06-30$6.16M$14.00K-$9.75M
2022-06-30$3.93M$14.00K-$6.87M
2021-06-30$4.56M$14.00K-$6.90M
2020-06-30$2.95M$18.00K-$4.90M
2019-06-30$4.48M$17.00K-$5.72M
2018-06-30$1.86M$18.00K-$2.38M

Revenue and expense 9 month

Period endRevenue including taxResearch and developmentIncome taxNet income
2025-09-30(m)$17.91M$18.00K-$24.03M
2024-09-30(m)$12.59M$21.00K-$16.54M
2023-09-30(m)$9.43M$21.00K-$14.22M
2022-09-30(m)$5.57M$21.00K-$9.93M
2021-09-30(m)$6.89M$21.00K-$10.35M
2020-09-30(m)$5.11M$20.00K-$8.09M
2019-09-30(m)$6.10M$29.00K-$8.17M
2018-09-30$500.00K$3.07M$74.00K-$3.77M

Revenue and expense 12 month

Period endRevenue including taxResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$24.61M$34.40M$28.00K-$32.77M
2024-12-31(m)$19.06M$26.68M$30.00K-$24.44M
2023-12-31(m)$13.11M$21.27M$43.00K-$19.38M
2022-12-31(m)$7.84M$14.00M$28.00K-$13.68M
2021-12-31(m)$8.77M$13.65M$28.00K-$13.59M
2020-12-31(m)$8.21M$12.70M$27.00K-$12.29M
2019-12-31(m)$7.90M$11.59M$31.00K-$10.65M
2018-12-31$500.00K$4.52M$7.26M$80.00K-$5.73M
2017-12-31(m)$3.21M$4.52M(m)-$4.26M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68